Allies Voice - Your Comments on the Diabetes News: Recent Comments

Comment on Promising Companies for the Future of Diabetes

2010-04-15T19:22:47Z

I hope your dose of Lasix or other diuretic continues to be effective long enough for you to have a pre-emptive transplant prior to dialysis. If not, then keep in mind that Benfotiamine is helpful to dialysis patients as well: See N. Schupp, et al, "Benfotiamine Reduces Genomic Damage in Peripheral Lymphocytes of Hemodialysis Patients," Naunyn-Schmiedebergs Archiv of Pharmacology, 378(3)283(2008).

The only 'cures' with any prospect of providing benefit for patients within the next decade or so are stem-cell transplants, which are already available for patients at German clinics, but which carry a high risk of carcinogenesis, and xenograft porcine beta cell implants, which are already being tested with good results in human subjects in Russia and New Zealand by Living Cell Technologies. They anticipate general commercial availability of their product within two or three years, but so far all it has proved able to do is to reduce but not eliminate the need for insulin injections. It also has a short survival period and must be replaced every few years, which gets pretty expensive at an estimated cost of $100,000 a year. Cerco Medical has a much better encapsulation device which may improve efficiency, allow for complete avoidance of injected insulin, and ultimately do all of this at a cheaper price, but its research is a few years behind LCT's.

The major problem is that all of the lines of research currently being pursued are based on the assumption that once the blood sugar abnormality of diabetes is corrected, all the other abnormalities, known as complications, will magically disappear. But the best evidence today indicates that the complications are caused in whole or in part by genetic factors inherited along with the genes which predispose individuals to manifest a blood sugar abnormality or by the continuing autoimmune disease whose first but by no means last expression is the destruction of the beta cells of the pancreas. See M. Jahromi, et al, "Significant Correlation between Association of Polymorphism in Codon 10 of the Transforming Growth Factor Beta 17 (29) C with Diabetes and Patients with Nephropathy Disorder," Journal of Interferon and Cytokine Research, 19 Dec. 2009 and T. Staeva-Vieira, et al, "Translational Mini-Review Series on Type 1 Diabetes: Immune-Based Therapeutic Approaches," Clinical and Experimental Immunology, 148, 17 (2007).

Comment on Promising Companies for the Future of Diabetes

2010-04-14T16:06:56Z

LCT seems very promising to me. Also Cerco medical but they have a long way to go.

Comment on Promising Companies for the Future of Diabetes

2010-04-10T16:54:34Z

Allie. I don't have a suggestion of a company, but you must have a list of those that would be interesting to research.

Comment on Promising Companies for the Future of Diabetes

2010-04-09T20:42:38Z

Glad your back Allie, did you ever try Dr Bernstein's regiment of low carb which would reduce the amount of insulin needed and the glucose swings.

Comment on Promising Companies for the Future of Diabetes

2010-04-09T08:03:30Z

http://www.Amazon.com/Fresh-Vegetable-Fruit-Juices-Walker/dp/089019033X/ref=tmm_pap_title_0

or

Gerson therapy [for kidney healing] ...

http://www.YouTube.com/watch?v=ShqKk3fasZA

http://www.YouTube.com/watch?v=H2RL6lt2H1A

http://www.YouTube.com/watch?v=zWARBF_eR2A

Comment on Promising Companies for the Future of Diabetes

2010-04-09T02:24:07Z

Gosh I hope U make out OK Allie + yeah I do Hope a Cure comes along soon for Everybody. It's about Time.

Comment on Promising Companies for the Future of Diabetes

2010-04-09T00:58:35Z

Aside from the well-publicized firms (Macrogenics, Tolerx, Transition Therapeutics, Exsulin), there are a few startups that I'd like to see more about. One is Toronto-based Diabecore Medical (www.diabecore.com) and the insulin they're developing called "Hypoguard" which is the first insulin analogue I'm aware of that would not cause hypoglycemia. Today, Wilmington, Delaware-based CureDM Group Holdings LLC signed a deal with Sanofi Aventis, this is an autoimmunity-based treatment that would put the French company in line with rivals Lilly and Novo Nordisk, which also have autoimmunity treatments in development.

Comment on LA Times article about Tight Diabetes

2010-04-03T11:41:20Z

*
Apparently blood glucose concentration rises, especially from increased gluconeogenesis in combination with GLUT4 glucose / insulin resistance, to help protect nerve tissue from blood fuel shortages. That protective adaption is often called diabetes and 'Diabetics' are often treated with glucose fuel lowering drugs instead of improved ... hydration to prevent dehydration & nutrition to prevent neurological fuel shortage.
#

... LOVEingly :) Nick Gracey, WATerian @ 1234hrs SAT.03.APR.2010